188 related articles for article (PubMed ID: 32383803)
1. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
Cancer; 2020 Jul; 126(14):3360-3371. PubMed ID: 32383803
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA
Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway.
Yu Z; Zhang C; Wang H; Xing J; Gong H; Yu E; Zhang W; Zhang X; Cao G; Fu C
Cancer Lett; 2014 Oct; 353(2):182-93. PubMed ID: 25088576
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
Park JH; Kim YH; Park EH; Lee SJ; Kim H; Kim A; Lee SB; Shim S; Jang H; Myung JK; Park S; Lee SJ; Kim MJ
Cancer Sci; 2019 Sep; 110(9):2834-2845. PubMed ID: 31278880
[TBL] [Abstract][Full Text] [Related]
5. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
[TBL] [Abstract][Full Text] [Related]
6. Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer.
Fernandes JM; Jandrey EHF; Koyama FC; Leite KRM; Camargo AA; Costa ÉT; Perez RO; Asprino PF
Dis Colon Rectum; 2020 Jul; 63(7):918-926. PubMed ID: 32229782
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
[TBL] [Abstract][Full Text] [Related]
9. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
Löcken H; Clamor C; Müller K
J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
[TBL] [Abstract][Full Text] [Related]
10. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
Li X; Wei Y; Wei X
Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
[TBL] [Abstract][Full Text] [Related]
11. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
Hubbard JM; Grothey A
Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
[TBL] [Abstract][Full Text] [Related]
12. Napabucasin prevents brain injury in neuronal neonatal rat cells through suppression of apoptosis and inflammation.
Wang J; Feng H; Li Z; Zhang X
Microb Pathog; 2019 Mar; 128():337-341. PubMed ID: 30659911
[TBL] [Abstract][Full Text] [Related]
13. The small molecule AU14022 promotes colorectal cancer cell death via p53-mediated G2/M-phase arrest and mitochondria-mediated apoptosis.
Ryu H; Nam KY; Kim JS; Hwang SG; Song JY; Ahn J
J Cell Physiol; 2018 Jun; 233(6):4666-4676. PubMed ID: 29030986
[TBL] [Abstract][Full Text] [Related]
14. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer.
Chen J; Wang J; Lin L; He L; Wu Y; Zhang L; Yi Z; Chen Y; Pang X; Liu M
Mol Cancer Ther; 2012 Feb; 11(2):277-87. PubMed ID: 22203730
[TBL] [Abstract][Full Text] [Related]
16. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
Chang AY; Hsu E; Patel J; Li Y; Zhang M; Iguchi H; Rogoff HA
Mol Cancer Res; 2019 Jul; 17(7):1429-1434. PubMed ID: 31043490
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
19. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
[TBL] [Abstract][Full Text] [Related]
20. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
